[1] |
葛均波,徐永健,王辰主编. 内科学[M].北京:人民卫生出版社,2018:261-271
|
[2] |
Janssen EM, Dy SM, Meara AS, et al.Analysis of Patient Preferences in Lung Cancer - Estimating Acceptable Tradeoffs Between Treatment Benefit and Side Effects[J]. Patient Prefer Adherence, 2020,14:927-937.
|
[3] |
Fu M, Kontogeorgos S, Thunstrom E, et al.Trends in myocarditis incidence, complications and mortality in Sweden from 2000 to 2014[J]. Sci Rep, 2022, 12(1):1810.
|
[4] |
Pahuja M, Adegbala O, Mishra T, et al.Trends in the Incidence of In-Hospital Mortality, Cardiogenic Shock, and Utilization of Mechanical Circulatory Support Devices in Myocarditis (Analysis of National Inpatient Sample Data, 2005-2014)[J]. J Card Fail, 2019, 25(6):457-467.
|
[5] |
Ammirati E, Cipriani M, Moro C, et al.Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis: Multicenter Lombardy Registry. Circulation, 2018, 138(11):1088-1099.
|
[6] |
Younis A, Matetzky S, Mulla W, et al.Epidemiology Characteristics and Outcome of Patients With Clinically Diagnosed Acute Myocarditis[J]. Am J Med, 2020, 133(4):492-499.
|
[7] |
Oka E, Iwasaki YK, Maru Y, et al.Prevalence and Significance of an Early Repolarization Electrocardiographic Pattern and Its Mechanistic Insight Based on Cardiac Magnetic Resonance Imaging in Patients With Acute Myocarditis[J].Circ Arrhythm Electrophysiol, 2019, 12(3):e6969.
|
[8] |
Janssen EM, Dy SM, Meara AS, et al.Analysis of Patient Preferences in Lung Cancer - Estimating Acceptable Tradeoffs Between Treatment Benefit and Side Effects[J].Patient Prefer Adherence, 2020, 14:927-937.
|
[9] |
Lehmann LH, Cautela J, Palaskas N, et al.Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor -Associated Myocarditis: A Narrative Review[J].JAMA Cardiol, 2021, 6(11):1329-1337.
|
[10] |
陈素华,刘红,张艳华.紫杉烷类抗肿瘤药物相关心血管毒性报告及文献分析[J].中国新药杂志,2020,29(20):2395-2400.
|
[11] |
邰宵辉,李红玲,党春艳等.抗肿瘤药物致心脏毒性41例临床分析[J].中国心血管病研究,2022,20(5):422-426.
|